| ID Source | ID |
|---|---|
| PubMed CID | 3080935 |
| MeSH ID | M0092386 |
| Synonym |
|---|
| l-cysteine, n-acetyl-, ester with glycine 2-((dichloroacetyl)amino)-3-hydroxy-3-(4-(methylsulfonyl)phenyl)propyl ester, (r-(r*,r*))- |
| einecs 278-282-1 |
| n-acetyl-l-cysteine, ester with (r-(r*,r*))-2-(dichloroacetamido)-3-hydroxy-3-(p-mesylphenyl)propyl glycinate |
| acetylcysteinate ester of thiamphenicol glycinate |
| thiamphenicol glycinate acetylcysteinate |
| fluimucil antibiotic (tn) |
| 75639-30-4 |
| D08582 |
| [(2r,3r)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-methylsulfonylphenyl)propyl] 2-amino-3-[[(2r)-1-methylsulfanyl-3-oxopropan-2-yl]amino]-3-oxopropanoate |
| DTXSID30997070 |
| 2,2-dichloro-n-{1-hydroxy-1-[4-(methanesulfonyl)phenyl]-3-[(3-{[1-(methylsulfanyl)-3-oxopropan-2-yl]imino}seryl)oxy]propan-2-yl}ethanimidic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Both treatments were well tolerated with fewer than 5% of patients experiencing an adverse event." | ( Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. De Benedetto, F; Grassi, C, 2002) | 0.56 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Although the in vitro activity of the tested drugs evaluated by time-kill curves seemed comparable, some pharmacokinetic and pharmacodynamic characteristics of TGA contribute to improving the resolution of the infective process." | ( Comparative effect of thiamphenicol glycinate, thiamphenicol glycinate N-acetylcysteinate, amoxicillin plus clavulanic acid, ceftriaxone and clarithromycin on pulmonary clearance of Haemophilus influenzae in an animal model. De Vecchi, E; Drago, L; Fassina, MC; Gismondo, MR; Lombardi, A; Mombelli, B, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thiamphenicol is present as glycinate hydrochloride (TG) and glycinate acetylcysteinate (TGA) esters in the parenteral and aerosol dosage form." | ( Recent clinical evidence of the efficacy and safety of thiamphenicol glycinate acetylcysteinate and thiamphenicol glycinate. De Benedetto, F; Grassi, C, 2002) | 0.56 |
| " Patients were randomized to treatment with thiamphenicol glycinate acetylcysteinate, dosage 250 mg/day in 2 administrations plus beclomethasone with a dosage of 400 microg/day in 2 administrations, or no treatment, control group, unless required." | ( Aerosol antibiotic therapy in children with chronic upper airway infections: a potential alternative to surgery. Castelnuovo, P; Macchi, A, ) | 0.39 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||